Unit costs in international economic evaluations: Resource costing of the Schizophrenia Outpatient Health Outcomes Study

Acta Psychiatrica Scandinavica, Supplement

Volumn 107, Issue 416, 2003, Pages 41-47

  Urdahl, H ^a   Knapp, M ^b,c   Edgell, Eric T ^d   Ghandi, G ^d   Haro, J M ^e  

^a UNIVERSITY OF YORK   (United Kingdom)

^b LONDON SCHOOL OF ECONOMICS   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d ELI LILLY AND COMPANY   (United States)

^e PARC SANITARI SANT JOAN DE DÉU   (Spain)

Author keywords

Antipsychotic agents; Europe; Health care costs; Outcome assessment (health care); Outpatients; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT; OLANZAPINE;

ARTICLE; CONTROLLED STUDY; COST; DAY CARE; ECONOMIC EVALUATION; EUROPE; HEALTH CARE; HOSPITAL ADMISSION; HUMAN; MEDICAL FEE; OUTPATIENT; SCHIZOPHRENIA; TREATMENT OUTCOME; ADULT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HEALTH CARE COST; INTERNATIONAL COOPERATION; OUTCOMES RESEARCH; OUTPATIENT CARE; PRIORITY JOURNAL; AMBULATORY CARE; ECONOMICS; MENTAL HEALTH SERVICE; MULTICENTER STUDY; PROSPECTIVE STUDY; STATISTICS;

AMBULATORY CARE; EUROPE; HEALTH CARE COSTS; HUMANS; MENTAL HEALTH SERVICES; PROSPECTIVE STUDIES; SCHIZOPHRENIA;

EID: 0038180347     PISSN: 00651591     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0447.107.s416.2.x     Document Type: Article

References (30)

1. WILLKE RJ, GLICK H, POLSKY D et al. Estimating country-specific cost-effectiveness from multinational clinical trials. Health Econ 1998;7:481-493.
2. MURRAY CJL, EVANS DB, ACHARVA A, BALTUSSEN R. Development of WHO guidelines on generalised cost-effectiveness analysis. Health Econ 2000;9:235-251.
3. DRUMMOND MF, BLOOM BS, CARRIN G et al. Issues in the cross-national assessment of health technology. Int J Technol Assess Health Care 1992;8:671-682.
4. JONSSON B, JOHANNESSON M, KJEKSHUS J, OLSSON AG, PEDERSEN TR, WEDEL H. Cost-effectiveness of cholesterol lowering: results from the Scandinavian Simvastatin Survival Study (4S). Eur Heart J 1996;17:1001-1007.
5. RABAH M, MASON D, MULLER DWM et al. Heparin after percutaneous intervention (HAPI): a prospective multicenter randomised trial of three heparin regimens after successful coronary intervention. J Am Coll Cardiol 1999;34:461-467.
6. SCHULMAN KA, BUXTON M, GLICK H et al. Results of the economic evaluation of the FIRST study. A multinational prospective economic evaluation. Int J Technol Assess Health Care 1996;12:698-713.
7. GLICK H, WILLKE R, POLSKY D et al. Economic analysis of tirilazad mesylate for aneurysmal subarachnoid hemorrhage: economic evaluation of a phase III clinical trial in Europe and Australia. Int J Technol Assess Health Care 1998;14:145-160.
8. O'BRIEN BJ. A tale of two (or more) cities: geographic transferability of pharmacoeconomic data. Am J Manag Care 1997;3:S33-S39.
9. NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE (NICE). Technical guidance for manufacturers and sponsors on making a submission to a technology appraisal. March, 2001. http://www.nice.org.uk.
10. OOSTENBRINK JB, KOOPMANSCHAP MA, RUTTEN FFH. Handleiding voor kostenonderzoek, methoden en richtlijnprijzen voor economische evaluaties in de gezondheidszorg. Amstelveen: College for Health Care Insurance, 2000:1-26.
11. KNAPP MRJ. The economic perspective: framework and principles. In: KNAPP MRJ, ed. The economic evaluation of mental health care. Aldershot: Ashgate, 1995.
12. RUTTEN-VAN MOLKEN MPMH, VAN DORSLAER EKA, TILL MD. Cost-effectiveness analysis of formoterol versus salmeterol in patients with asthma. Pharmacoeconomics 1998;14:671-684.
13. MARK DB, HARRINGTON RA, LINCOFF AM et al. Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes. Circulation 2000;101:366-371.
14. BALL SG. Cost-effectiveness of ramipril therapy for patients with clinical evidence of heart failure after acute myocardial infarction. Br J Clin Pract 1995;(Suppl. 78):26-32.
15. RAIKOU M, BRIGGS A, GRAY A, MCGUIRE A. Centre-specific or average unit costs in multi-centre studies? Some theory and simulation. Health Econ 2000;9:191-198.
16. JONSSON B, WEINSTEIN MMC. Economic evaluation alongside multinational clinical trials. Study considerations for GUSTO IIb. Int J Technol Assess Health Care 1997;13:49-58.
17. PANG F. Design, analysis and presentation of multinational economic studies. Pharmacoeconomics 2002;20:75-90.
18. HARO JM, EDGELL ET, JONES PB et al. on behalf of the SOHO STUDY GROUP. The European Schizophrenia Outpatient Health Outcome (SOHO) Study: rationale, methods and recruitment. Acta Psychiatr Scand 2003; 107:222-232.
19. ORGANISATION FOR ECONOMIC CO-OPERATION AND DEVELOPMENT (OECD). Main economic indicators. November, 2001. http://www.oecd.com.
20. KNAPP MRJ, CHISHOLM D, LEESE M et al. Comparing patterns and costs of schizophrenia care in five European countries: the EPSILON study. Acta Psychiatr Scand 2002;105:42-54.
21. SCHULMAN K, BURKE J, DRUMMOND M et al. Resource costing for multinational clinical trials, methods and results. Health Econ 1998;7:629-638.
22. NETTEN A, DENNET J, KNIGHT J, eds. Unit cost of health and social care. Canterbury: Personal Social Services Research Unit (PSSRU), 2000.
23. Einheitlicher Bewertungsmaßstab (eBm). Cologne: Deutsche Ärzte Verlag, 2001.
24. NOMENKLATORE TARIFFARIO REGIONALE. Aggiornamento del Nomenclatore tariffario delle prestazioni di assistenza specialistica e ambulatoriale. Parte seconda, anno 31, no. 67. Bologna: Bollettino Ufficiale Regione Emilia-Romagna, 2000;17 April.
25. Diário da República. Portaria no. 189. 2001, March 9.
26. SALVADOR-CARULLA L, HARO JM, CABASÉS J et al. Service utilization and costs of first-onset schizophrenia in two extreme health scenarios in north-eastern Spain. Acta Psychiatr Scand 1999;100:1-9.
27. HARO JM, SALVADOR-CARULLA L, CABASÉS J et al. Mental health services utilization and costs of patients with schizophrenia in three areas of Spain. Br J Psychiatry 1998;173:334-340.
28. DRUMMOND MF, STODDART GL, TORRANCE GW. Methods for the economic evaluation of health care programs. New York: Oxford University Press Inc., 1987:39-71.
29. JOHANNESSON M. A note on the depreciation of the societal perspective in economic evaluation of health-care. Health Policy 1995;33:59-66.
30. BROUWER W, RUTTEN F, KOOPMANSCHAP M. Costing in economic evaluation. In: DRUMMOND M, MCGUIRE A, eds Economic evaluation in health care: merging theory with practise. Oxford: Oxford University Press, 2001:68-93.